Home » EMA Draft Policy Calls for ‘Considered Approach’ on Trial Transparency
EMA Draft Policy Calls for ‘Considered Approach’ on Trial Transparency
July 10, 2013
The European Medicines Agency last month unveiled its proposed policy for increasing access to clinical trial data, offering a “considered approach” to transparency that respects patient and commercial interests.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor